Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/21645515.2015.1021528 http://scihub22266oqcxt.onion/10.1080/21645515.2015.1021528 C4514158!4514158 !25901415     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25901415 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Hum+Vaccin+Immunother 2015 ; 11 (5 ): 1258-60 Nephropedia Template TP {{tp|p=25901415 |t=2015. A vaccine against Ebola: Problems and opportunities |pdf=|usr=}}{{25901415 }} gab.com Text A vaccine against Ebola: Problems and opportunities JO: Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=25901415 #FOAvip The unprecedented dimensions of the 2014 Ebola epidemic which ravaged 3 West African countries have challenged public health response capacity and urged the availability of safe and effective vaccines. In this context, vectored vaccines already tested in animal models have undergone phase 1 studies in human beings and are now ready for efficacy evaluation in large scale trials. Health care workers and other frontline caregivers are likely to be the target population for both vaccine trials and vaccination campaigns. However, methodological and ethical issues should be considered in plans concerning the conduction of clinical trials and the possible use of licensed vaccines against Ebola. Twit Text FOAVip A vaccine against Ebola: Problems and opportunities ????Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=25901415 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25901415 #FOAvip English Wikipedia <ref>{{Cite pmid|25901415 }}</ref> A vaccine against Ebola: Problems and opportunities #MMPMID25901415 Rezza G Hum Vaccin Immunother 2015[]; 11 (5 ): 1258-60 PMID25901415 show ga The unprecedented dimensions of the 2014 Ebola epidemic which ravaged 3 West African countries have challenged public health response capacity and urged the availability of safe and effective vaccines. In this context, vectored vaccines already tested in animal models have undergone phase 1 studies in human beings and are now ready for efficacy evaluation in large scale trials. Health care workers and other frontline caregivers are likely to be the target population for both vaccine trials and vaccination campaigns. However, methodological and ethical issues should be considered in plans concerning the conduction of clinical trials and the possible use of licensed vaccines against Ebola. |Africa, Western/epidemiology [MESH] |Clinical Trials, Phase I as Topic [MESH] |Drug Discovery/*methods/trends [MESH] |Ebola Vaccines/adverse effects/*immunology [MESH] |Hemorrhagic Fever, Ebola/*prevention & control [MESH]A vaccine against Ebola: Problems and opportunities (epmc).pdf DeepDyve Pubget Overpricing